Related references
Note: Only part of the references are listed.Tumor Shrinkage With Combination of Alectinib and Trastuzumab in a Patient With ALK-Rearranged Non-small Cell Lung Cancer Harboring HER2-Amplification as an Acquired Resistance Mechanism to ALK Inhibitor Therapy
David Chun Cheong Tsui et al.
CLINICAL LUNG CANCER (2022)
Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non-Small-Cell Lung Cancer
Mohammad Jahanzeb et al.
CLINICAL LUNG CANCER (2021)
Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression
Azusa Tanimoto et al.
CLINICAL CANCER RESEARCH (2021)
ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib
Edward S. Kim et al.
FUTURE ONCOLOGY (2021)
Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial
Makoto Nishio et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Will the clinical development of 4th-generation double mutant active ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK plus NSCLC?
Sai-Hong Ignatius Ou et al.
TRANSLATIONAL ONCOLOGY (2021)
Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib
Jingran Ji et al.
CLINICAL LUNG CANCER (2021)
Brigatinib vs Alectinib in Crizotinib-Resistant Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer (ALTA-3)
Sanjay Popat et al.
FUTURE ONCOLOGY (2021)
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
D. Ross Camidge et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC : Initial Results of the Phase 2 ALK-Positive Cohort
Rafal Dziadziuszko et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations
Brion W. Murray et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer A Randomized Clinical Trial
Leora Horn et al.
JAMA ONCOLOGY (2021)
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer
Vanita Noronha et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer
Gonzalo Recondo et al.
CLINICAL CANCER RESEARCH (2020)
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study
Yukio Hosomi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study
Enriqueta Felip et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial
Rudolf M. Huber et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer
Ibiayi Dagogo-Jack et al.
CLINICAL CANCER RESEARCH (2020)
Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer
Sachiko Arai et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer
Kazuhiko Nakagawa et al.
LUNG CANCER (2020)
Phase Ib Study of Crizotinib Plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation
Sandip Pravin Patel et al.
ONCOLOGIST (2020)
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study
T. Mok et al.
ANNALS OF ONCOLOGY (2020)
Comparison of liquid-based to tissue-based biopsy analysis by targeted next generation sequencing in advanced non-small cell lung cancer: a comprehensive systematic review
Stepan M. Esagian et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)
EML4-ALK V3 oncogenic fusion proteins promote microtubule stabilization and accelerated migration through NEK9 and NEK7
Laura O'Regan et al.
JOURNAL OF CELL SCIENCE (2020)
BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer
Ruoshi Shi et al.
LUNG CANCER (2020)
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
D. Ross Camidge et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Durable complete response after afatinib and crizotinib in an advanced non-small cell lung cancer patient with EGFR L861Q mutation and acquired MET amplification: a case report
Yaling Long et al.
ANNALS OF PALLIATIVE MEDICINE (2020)
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
TPX-0131: A next generation macrocyclic ALK inhibitor that overcomes ALK resistant mutations refractory to current approved ALK inhibitors
J. Jean Cui et al.
CANCER RESEARCH (2020)
Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion
Quincy S. Chu
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Identification of a highly lethal V3+TP53+ subset in ALK+ lung adenocarcinoma
P. Christopoulos et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model
Takahiro Tsuji et al.
MOLECULAR CANCER RESEARCH (2019)
Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status
Koji Fukuda et al.
CANCER RESEARCH (2019)
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study
D. Ross Camidge et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study
Byoung Chul Cho et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
108OTreatment duration of brigatinib in patients enrolled in the international expanded access program (EAP)
M M Lin et al.
ANNALS OF ONCOLOGY (2019)
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
J. Mazieres et al.
ANNALS OF ONCOLOGY (2019)
Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer
Natasha B. Leighl et al.
CLINICAL CANCER RESEARCH (2019)
Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up
Anna W. Chalmers et al.
TARGETED ONCOLOGY (2019)
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer
Mi Ran Yun et al.
EMBO MOLECULAR MEDICINE (2019)
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib
Geeta G. Sharma et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Comparative efficacy of first-line ceritinib and crizotinib in advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer: an adjusted indirect comparison with external controls
Junlong Li et al.
CURRENT MEDICAL RESEARCH AND OPINION (2019)
Non-Small Cell Lung Cancer, Version 1.2020 Featured Updates to the NCCN Guidelines
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
Kazuhiko Nakagawa et al.
LANCET ONCOLOGY (2019)
MYC Amplification as a Potential Mechanism of Primary Resistance to Crizonib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report
Karim Rihawi et al.
TRANSLATIONAL ONCOLOGY (2019)
Phase II study of ceritinib in alectinib-pretreated patients with anaplastic lymphoma kinase-rearranged metastatic non-small-cell lung cancer in Japan: ASCEND-9
Toyoaki Hida et al.
CANCER SCIENCE (2018)
Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
Leora Horn et al.
CLINICAL CANCER RESEARCH (2018)
EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK(+) non-small cell lung cancer
Petros Christopoulos et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer
Jessica J. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer
Benjamin J. Solomon et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370)
David R. Spigel et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
Christian Rolfo et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties
Merrida A. Childress et al.
MOLECULAR CANCER RESEARCH (2018)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D. Planchard et al.
ANNALS OF ONCOLOGY (2018)
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK plus ) non-small-cell lung cancer: CNS efficacy results from the ALEX study
S. Gadgeel et al.
ANNALS OF ONCOLOGY (2018)
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
A. Kron et al.
ANNALS OF ONCOLOGY (2018)
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Benjamin J. Solomon et al.
LANCET ONCOLOGY (2018)
Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer
C. G. Woo et al.
ANNALS OF ONCOLOGY (2017)
Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer
Masayoshi Miyawaki et al.
MOLECULAR CANCER RESEARCH (2017)
Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer
Ka-Won Noh et al.
JOURNAL OF PATHOLOGY (2017)
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Jean-Charles Soria et al.
LANCET (2017)
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
Solange Peters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients
Sarah R. Sabir et al.
CANCERS (2017)
Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer
Fiona Blackhall et al.
ESMO OPEN (2017)
Clinical Features of Bim Deletion Polymorphism and Its Relation With Crizotinib Primary Resistance in Chinese Patients With ALK/ROS1 Fusion-Positive Non-Small Cell Lung Cancer
Limin Zhang et al.
CANCER (2017)
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
Justin F. Gainor et al.
CLINICAL CANCER RESEARCH (2016)
Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2
Lucio Crino et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib
Yoon Jin Cha et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
Dong-Wan Kim et al.
LANCET ONCOLOGY (2016)
K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature
Maria Cecilia Mengoli et al.
LUNG CANCER (2016)
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
Justin F. Gainor et al.
CANCER DISCOVERY (2016)
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer
Ryohei Katayama et al.
EBIOMEDICINE (2016)
Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer
Keiichi Ota et al.
CLINICAL CANCER RESEARCH (2015)
CSF Concentration of Crizotinib in Two ALK-Positive Non-Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment
Giulio Metro et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers
Deepa Rangachari et al.
LUNG CANCER (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Mark G. Kris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer
Christine M. Lovly et al.
NATURE MEDICINE (2014)
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
Benjamin J. Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Patient-derived models of acquired resistance can identify effective drug combinations for cancer
Adam S. Crystal et al.
SCIENCE (2014)
Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions
Christine M. Lovly et al.
CANCER DISCOVERY (2014)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Anaplastic Lymphoma Kinase Is Required for Neurogenesis in the Developing Central Nervous System of Zebrafish
Sheng Yao et al.
PLOS ONE (2013)
Tyrosine kinase gene rearrangements in epithelial malignancies
Alice T. Shaw et al.
NATURE REVIEWS CANCER (2013)
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Ryohei Katayama et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
Takaaki Sasaki et al.
CANCER RESEARCH (2011)
CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
Daniel B. Costa et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed
D. Ross Camidge et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Anaplastic Lymphoma Kinase Translocation A Predictive Biomarker of Pemetrexed in Patients with Non-small Cell Lung Cancer
Jeong-Ok Lee et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
The biology and treatment of EML4-ALK non-small cell lung cancer
Takaaki Sasaki et al.
EUROPEAN JOURNAL OF CANCER (2010)
Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALK
Alice T. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer
Jussi P. Koivunen et al.
CLINICAL CANCER RESEARCH (2008)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3
Monika Kasprzycka et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target
R Chiarle et al.
NATURE MEDICINE (2005)
Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway
RY Bai et al.
BLOOD (2000)
Share Paper
